ArticleNature2019
VISTA is an acidic pH-selective ligand for PSGL-1.
Abstract read
In one paragraph
Article in Nature, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 266 papers.
0numbers the graph read from it
0cells of the map it votes in
266citing papers in PubMed
26.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
266 citing papers in PubMed, 381 citations in OpenAlex.
- Targeting myeloid cell plasticity and metabolic reprogramming to alleviate T cell dysfunction and exhaustion-associated states and enhance immune checkpoint blockade therapy.Biomarker research · 2026Review
- Targeting histamine signaling: repurposing antihistamines for cancer chemotherapy and immunotherapy.Archives of pharmacal research · 2026Review
- VISTA drives tumour-intrinsic proliferation in mesothelioma cells.British journal of cancer · 2026Article
- VISTA as a myeloid-centered checkpoint axis in cancer: biology, tumor microenvironment, and therapeutic implications.Medical oncology (Northwood, London, England) · 2026Review
- VISTA as a myeloid-centered checkpoint axis in cancer: biology, tumor microenvironment, and therapeutic implications.Medical oncology (Northwood, London, England) · 2026Review
- VISTA+ Neutrophils Contribute to Platinum Resistance by Suppressing CD8+ T Cells in High-Grade Serous Ovarian Cancer.Cancer immunology research · 2026Article
- Roles of V-domain Ig suppressor of T-cell activation-mediated immunoregulation in tumor immune escape (Review).Oncology letters · 2026Review
- A conserved grain-associated immunosuppressive niche in Sudanese patients with mycetoma.PLoS neglected tropical diseases · 2026Observational
- Role and clinical significance of VISTA (PD-1H) and PVR (CD155) expression in non-small cell lung carcinoma: a systematic review.Translational lung cancer research · 2026Review
- The pivotal role of macrophages in tumorigenesis and pioneering cancer immunotherapy across pre-clinical and clinical frontiers.Journal of cancer research and clinical oncology · 2026Review
- Peptide occupancy governs HLA-E checkpoint interactions enabling VISTA recognition of destabilized HLA-E conformers.Communications biology · 2026Article
- Inflammation and Colorectal Cancer Pathogenesis: Molecular, Immunological, and Environmental Features for Therapy Response and Resistances.International journal of molecular sciences · 2026Review
- Combined targeting of VISTA and sorafenib activates T cell-mediated anti-tumor immunity via the NF-κB/TNF axis in hepatocellular carcinoma.BMC medicine · 2026Article
- VISTA neutralization by immunization reprograms immunosuppression and augments vaccine efficacy in renal carcinoma.Journal for immunotherapy of cancer · 2026Article
- Tumor-infiltrating lymphocytes in triple-negative breast cancer: molecular mechanisms, spatial regulation, and therapeutic implications.Breast cancer research : BCR · 2026Review
- pH-Dependent Microenvironmental Ionic Signaling in Pancreatic Ductal Adenocarcinoma.Acta physiologica (Oxford, England) · 2026Review
- Immunosuppressive immune microenvironment landscapes in VISTA-high gastric cancer.British journal of cancer · 2026Article
- Exploring the role of metabolic disorders and gut microbiome in immune checkpoint regulation in cancer: PI3K/AKT/mTOR focus.Journal of physiology and biochemistry · 2026Review
- T cell-intrinsic VISTA expression promotes resistance to CTLA-4 blockade by restricting CD8+ T cell responses.The Journal of clinical investigation · 2026Article
- VISTA drives pancreatic tumor progression through modulation of the tumor-associated macrophage polarity.Nature communications · 2026Article
206 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
36 authors at 4 institutions in 2 countries.
Robert J JohnstonImmuno-Oncology Discovery, Bristol-Myers Squibb, Redwood City, CA, USA. robert.johnston@bms.com.
Linhui Julie Su *Selection Technologies and Protein Engineering, Bristol-Myers Squibb, Cambridge, MA, USA.
Jason Pinckney *Biomolecular Characterization, Bristol-Myers Squibb, Cambridge, MA, USA.
David Critton *Molecular Structure and Design, Bristol-Myers Squibb, Lawrenceville, NJ, USA.
Eric BoyerImmuno-Oncology Discovery, Bristol-Myers Squibb, Redwood City, CA, USA.
Arathi KrishnakumarProteomics Discovery, Bristol-Myers Squibb, Hopewell, NJ, USA.
Martin CorbettProtein Sciences, Bristol-Myers Squibb, Lawrenceville, NJ, USA.
Andrew L RankinImmuno-Oncology Discovery, Five Prime Therapeutics, South San Francisco, CA, USA.
Rose DibellaSelection Technologies and Protein Engineering, Bristol-Myers Squibb, Cambridge, MA, USA.
Lynne CampbellSelection Technologies and Protein Engineering, Bristol-Myers Squibb, Cambridge, MA, USA.
Gaelle H MartingenOway, Lyon, France.
Hadia LemarImmuno-Oncology Discovery, Bristol-Myers Squibb, Redwood City, CA, USA.
Thomas CaytonImmuno-Oncology Discovery, Bristol-Myers Squibb, Redwood City, CA, USA.
Richard Y-C HuangPharmaceutical Candidate Optimization, Bristol-Myers Squibb, Lawrenceville, NJ, USA.
Xiaodi DengProtein Therapeutics and Biologics Lead Discovery, Bristol-Myers Squibb, Redwood City, CA, USA.
Akbar NayeemMolecular Structure and Design, Bristol-Myers Squibb, Lawrenceville, NJ, USA.
Haibin ChenProtein Therapeutics and Biologics Lead Discovery, Bristol-Myers Squibb, Redwood City, CA, USA.
Burce ErgelProtein Sciences, Bristol-Myers Squibb, Lawrenceville, NJ, USA.
Joseph M RizzoProtein Sciences, Bristol-Myers Squibb, Lawrenceville, NJ, USA.
Aaron P YamniukProtein Sciences, Bristol-Myers Squibb, Lawrenceville, NJ, USA.
Sanjib DuttaBiomolecular Characterization, Bristol-Myers Squibb, Cambridge, MA, USA.
Justine NgoTranslational Sciences, Bristol-Myers Squibb, Lawrenceville, NJ, USA.
Andrea Olga ShortsTranslational Sciences, Bristol-Myers Squibb, Lawrenceville, NJ, USA.
Radha RamakrishnanPharmaceutical Candidate Optimization, Bristol-Myers Squibb, Lawrenceville, NJ, USA.
Alexander KozhichPharmaceutical Candidate Optimization, Bristol-Myers Squibb, Lawrenceville, NJ, USA.
Jim HollowayTranslational Bioinformatics, Bristol-Myers Squibb, Redwood City, CA, USA.
Hua FangLead Discovery and Optimization, Bristol-Myers Squibb, Lawrenceville, NJ, USA.
Ying-Kai WangLead Discovery and Optimization, Bristol-Myers Squibb, Lawrenceville, NJ, USA.
Zheng YangPharmaceutical Candidate Optimization, Bristol-Myers Squibb, Lawrenceville, NJ, USA.
Kader ThiamgenOway, Lyon, France.
Ginger RakestrawSelection Technologies and Protein Engineering, Bristol-Myers Squibb, Cambridge, MA, USA.
Arvind RajpalProtein Therapeutics and Biologics Lead Discovery, Bristol-Myers Squibb, Redwood City, CA, USA.
Paul SheppardImmuno-Oncology Discovery, Bristol-Myers Squibb, Redwood City, CA, USA.
Michael QuigleyImmuno-Oncology Discovery, Bristol-Myers Squibb, Redwood City, CA, USA.
Keith S BahjatImmuno-Oncology Discovery, Bristol-Myers Squibb, Redwood City, CA, USA.
Alan J KormanImmuno-Oncology Discovery, Bristol-Myers Squibb, Redwood City, CA, USA.
Bristol-Myers Squibb (United States) · USGenoway (France) · FRFive Prime Therapeutics (United States) · USVIR Biotechnology (United States) · US
Funding
No grant is acknowledged in the PubMed record.
Abstract
Co-inhibitory immune receptors can contribute to T cell dysfunction in patients with cancer
Indexed as
AnimalsAntibodies, BlockingB7 AntigensCD4-Positive T-LymphocytesCrystallography, X-RayEpitopes, B-LymphocyteFemaleHistidineHumansHydrogen-Ion ConcentrationLigandsMaleMembrane GlycoproteinsMiceModels, MolecularNeoplasmsAntibodies, BlockingB7 AntigensEpitopes, B-LymphocyteHistidineLigandsMembrane GlycoproteinsProgrammed Cell Death 1 ReceptorP-selectin ligand proteinVSIR protein, human
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.